Drug profile · INN
raltegravir potassium
RALTEGRAVIR VIATRIS
raltegravir potassium (RALTEGRAVIR VIATRIS) is a human immunodeficiency virus type 1 integrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — raltegravir potassium
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
raltegravir potassium (RALTEGRAVIR VIATRIS) is a human immunodeficiency virus type 1 integrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 integrase inhibitor
Primary target: Human immunodeficiency virus type 1 integrase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | application withdrawn | — |
| PMDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is raltegravir potassium?
raltegravir potassium (RALTEGRAVIR VIATRIS) is a human immunodeficiency virus type 1 integrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for raltegravir potassium?
RALTEGRAVIR VIATRIS is a marketed brand name for raltegravir potassium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of raltegravir potassium?
raltegravir potassium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.